• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. May 1996; 73(10): 1248–1254.
PMCID: PMC2074500

Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer.

Abstract

Risk of death and risk of recurrence in 108 potentially curable non-small-cell lung cancer patients were analysed with respect of TNM stage, histological type and carcinoembryonic antigen (CEA), CA125 antigen and squamous cell carcinoma antigen (SCC) levels in serum and cytosol. CA125 and CEA levels were closely related to outcome figures. Multivariate analyses indicated that TNM stage and histological type had the best predictive power, but serum and cytosolic CA125 and serum CEA contained additional, independent prognostic information. Predictive information drawn from serum and cytosolic levels proved mutually complementary. We conclude that CA125 and CEA complement TNM classification and histological type for the purpose of quantifying risk of death or recurrence.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Bains MS. Surgical treatment of lung cancer. Chest. 1991 Sep;100(3):826–837. [PubMed]
  • Bergman B, Brezicka FT, Engström CP, Larsson S. Clinical usefulness of serum assays of neuron-specific enolase, carcinoembryonic antigen and CA-50 antigen in the diagnosis of lung cancer. Eur J Cancer. 1993;29A(2):198–202. [PubMed]
  • Carney DN. Lung cancer biology. Eur J Cancer. 1991;27(3):366–369. [PubMed]
  • Diez M, Torres A, Pollán M, Gomez A, Ortega D, Maestro ML, Granell J, Balibrea JL. Prognostic significance of serum CA 125 antigen assay in patients with non-small cell lung cancer. Cancer. 1994 Mar 1;73(5):1368–1376. [PubMed]
  • Diez M, Gomez A, Hernando F, Ortega MD, Maestro ML, Torres A, Mugüerza JM, Gutierrez A, Granell J, Balibrea JL. Serum CEA, CA125, and SCC antigens and tumor recurrence in resectable non-small cell lung cancer. Int J Biol Markers. 1995 Jan-Mar;10(1):5–10. [PubMed]
  • Fielding LP, Fenoglio-Preiser CM, Freedman LS. The future of prognostic factors in outcome prediction for patients with cancer. Cancer. 1992 Nov 1;70(9):2367–2377. [PubMed]
  • Gail MH, Eagan RT, Feld R, Ginsberg R, Goodell B, Hill L, Holmes EC, Lukeman JM, Mountain CF, Oldham RK, et al. Prognostic factors in patients with resected stage I non-small cell lung cancer. A report from the Lung Cancer Study Group. Cancer. 1984 Nov 1;54(9):1802–1813. [PubMed]
  • Järvisalo J, Hakama M, Knekt P, Stenman UH, Leino A, Teppo L, Maatela J, Aromaa A. Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening. Cancer. 1993 Mar 15;71(6):1982–1988. [PubMed]
  • Lee JS, Hong WK. Prognostic factors in lung cancer. N Engl J Med. 1992 Jul 2;327(1):47–48. [PubMed]
  • Mountain CF. A new international staging system for lung cancer. Chest. 1986 Apr;89(4 Suppl):225S–233S. [PubMed]
  • Murren JR, Buzaid AC. Chemotherapy and radiation for the treatment of non-small-cell lung cancer. A critical review. Clin Chest Med. 1993 Mar;14(1):161–171. [PubMed]
  • Picardo AL, Torres AJ, Maestro M, Ortega D, Garcia-Asenjo JA, Mugüerza JM, Hernando F, Diez M, Balibrea JL. Quantitative analysis of carcinoembryonic antigen, squamous cell carcinoma antigen, CA 125, and CA 50 cytosolic content in non-small cell lung cancer. Cancer. 1994 May 1;73(9):2305–2311. [PubMed]
  • Sánchez De Cos J, Masa F, de la Cruz JL, Disdier C, Vergara C. Squamous cell carcinoma antigen (SCC Ag) in the diagnosis and prognosis of lung cancer. Chest. 1994 Mar;105(3):773–776. [PubMed]
  • Shepherd FA. Future directions in the treatment of non-small cell lung cancer. Semin Oncol. 1994 Jun;21(3 Suppl 4):48–62. [PubMed]
  • Shinkai T, Saijo N, Tominaga K, Eguchi K, Shimizu E, Sasaki Y, Fujita J, Futami H, Ohkura H, Suemasu K. Serial plasma carcinoembryonic antigen measurement for monitoring patients with advanced lung cancer during chemotherapy. Cancer. 1986 Apr 1;57(7):1318–1323. [PubMed]
  • Spiridonidis CH, Laufman LR, Stydnicki KA, Noltimier JW, Cho CC, Young DC, Hicks WJ, Segal ML, Guy JT, Zidar BL. Decline of posttreatment tumor marker levels after therapy of nonsmall cell lung cancer. A useful outcome predictor. Cancer. 1995 Apr 1;75(7):1586–1593. [PubMed]
  • Strauss GM, Skarin AT. Use of tumor markers in lung cancer. Hematol Oncol Clin North Am. 1994 Jun;8(3):507–532. [PubMed]
  • Strauss GM, Kwiatkowski DJ, Harpole DH, Lynch TJ, Skarin AT, Sugarbaker DJ. Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung. J Clin Oncol. 1995 May;13(5):1265–1279. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...